Psychiatr. praxi. 2016;17(2):63-64 | DOI: 10.36290/psy.2016.016
Agomelatine in treating depression as an alternative in SSRI intolerance
- Klinika psychiatrie Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého v Olomouci
Antidepressants are among the most frequently prescribed drugs in developed countries. The clinical practice shows the constant need for expanded pharmacological options of effective antidepressant therapy. Substantial amounts have been spent on research into novel antidepressants. In spite of this, only a few novel effective agents have been presented in the recent years. These include agomelatine that was introduced into the market in the European Union in 2009 and is indicated for the treatment of depression in adults.
Keywords: depression, anxiety, insomnia, circadian rhythms, agomelatine
Published: June 10, 2016 Show citation
References
- Kennedy SH, Avedisova A, Bela?di C, Picarel-Blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016; 26(2): 378-389.
Go to original source... 
Go to PubMed... - Urade CS, Mahakalkar SM, Tiple PG. A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study. J Pharmacol Pharmacother. 2015; 6(4): 198-203. Go to original source... Go to PubMed...
- Thome J, Foley P. Agomelatine: an agent against anhedonia and abulia? J Neural Transm (Vienna).2015; 122(Suppl1): S3-7. Go to original source... Go to PubMed...
- Martinotti G, Pettorruso M, De Berardis D, Varasano PA, Lucidi Pressanti G, De Remigis V, Valchera A, Ricci V, Di Nicola M, Janiri L, Biggio G, Di Giannantonio M. Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms. Int J Neuropsychopharmacol. 2016 [Epub ahead of print]. Go to original source... Go to PubMed...
- Laux G, VIVALDI Study Group. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012; 45(7): 284-291. Go to original source... Go to PubMed...
- Komaram RB, Nukala S, Palla J, Nambaru LR, Kasturi SM. A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder. J Clin Diagn Res. 2015; 9(6): VC05-VC08.
- Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50 mg or fluoxetine 20-40 mg in Asian out-patients with major depressive disorder. Asian J Psychiatr. 2014; 8: 26-32. Go to original source... Go to PubMed...
- Huang KL, Lu WC, Wang YY, Hu GC, Lu CH, Lee WY, Hsu CC. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. Aust N Z J Psychiatry. 2014; 48(7): 663-671. Go to original source...
- Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013; 12: CD008851. Go to original source...
- Teicher MH, Glod C, Cole JO. Emergence of intense suicidal pre-occupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210. Go to original source... Go to PubMed...
- Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991; 303: 685-692. Go to original source... Go to PubMed...
- Healy D. Emergence of antidepressant induced suicidality. Primary Care Psychiatry 2000; 6: 23-28. Go to original source...
- Leslie LK, Newman TB, Chesney PJ, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics. 2005; 116(1): 195-204. Go to original source... Go to PubMed...